Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00196638 |
Recruitment Status
:
Terminated
First Posted
: September 20, 2005
Last Update Posted
: August 29, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections Primary Acute Infection | Drug: Antiretroviral combination (drugs) Drug: Pegylated Interferon alpha (drug) | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection.ANRS 112 INTERPRIM |
Study Start Date : | May 2002 |
Study Completion Date : | March 2006 |

- Plasma HIV RNA at Week 92 and 96 (mean)
- Plasma HIV RNA kinetics after treatment interruption
- CD4 cell count
- Proviral DNA
- Adherence

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- P24 antigen with positive neutralization or positive plasma HIV RNA
- Negative or not complete Western Blot
- With symptoms or not
- Written informed consent
Exclusion Criteria:
- Previous antiretroviral treatment
- Pregnancy
- Biological abnormalities
- Hepatitis C or B

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00196638
Principal Investigator: | Dominique Emilie, MD | Hôpital Antoine Béclère, Clamart, France | |
Study Director: | Genevieve Chene, MD, PhD | INSERM U593, Bordeaux, France. |
ClinicalTrials.gov Identifier: | NCT00196638 History of Changes |
Other Study ID Numbers: |
ANRS 112 INTERPRIM |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | August 29, 2006 |
Last Verified: | August 2006 |
Keywords provided by French National Agency for Research on AIDS and Viral Hepatitis:
HIV infections Primary acute infection Interferon-alpha |
Additional relevant MeSH terms:
Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Interferons Interferon-alpha Antineoplastic Agents Antiviral Agents Anti-Infective Agents Immunologic Factors Physiological Effects of Drugs |